Drug intelligence / Profile preview

curcumin

Development stage
Phase 4
Lead developer
DolCas Biotech
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

**Curcumin** is a plant-derived polyphenolic diarylheptanoid and the principal curcuminoid found in turmeric, the rhizome of *Curcuma longa*. It is a chemically defined small molecule rather than turmeric powder or a mixed curcuminoid extract. Curcumin has been widely studied as an oral nutraceutical and investigational therapeutic for metabolic disorders, inflammatory diseases, fatty liver disease, depression, cancer supportive care, and cancer cachexia. It has low intrinsic oral bioavailability because of limited absorption and rapid metabolism and elimination; many clinical studies therefore use enhanced-bioavailability formulations, which are distinct products from unformulated curcumin. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Curcumin)) Its pharmacology is pleiotropic, with reported suppression of inflammatory signaling including NF-kappa B pathways and modulation of oxidative-stress responses, but no single clinically validated primary molecular target has been established. Curcumin is sold predominantly as a dietary supplement and is not an approved pharmaceutical treatment for the diseases listed here. ([nccih.nih.gov](https://www.nccih.nih.gov/health/turmeric?here%E2%80%99s_what_to_expect=))

Brand names
Theracurmin HP
Other names
diferuloylmethanecurcumin I
02

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)JNK (Mitogen-activated protein kinase kinase kinase family)MAPK14 (p38 mitogen-activated protein kinase alpha)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)IKBKB (IKKβ)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)NF-κB

Beyond the preview

Go deeper on curcumin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on curcumin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call